UBS Group’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-47,824
| Closed | -$2.3M | – | 8754 |
|
|
2020
Q1 | $2.3M | Buy |
47,824
+28,292
| +145% | +$1.32M | ﹤0.01% | 2634 |
|
|
2019
Q4 | $917K | Sell |
19,532
-92,349
| -83% | -$4.08M | ﹤0.01% | 4301 |
|
|
2019
Q3 | $2.65M | Buy |
111,881
+86,337
| +338% | +$2.56M | ﹤0.01% | 3024 |
|
|
2019
Q2 | $768K | Buy |
25,544
+23,716
| +1,297% | +$543K | ﹤0.01% | 3957 |
|
|
2019
Q1 | $41K | Buy |
1,828
+198
| +12% | +$4.26K | ﹤0.01% | 5710 |
|
|
2018
Q4 | $30K | Buy |
+1,630
| New | +$25.6K | ﹤0.01% | 6494 |
|
|
2018
Q3 | – | Sell |
-5,171
| Closed | -$51K | – | 8449 |
|
|
2018
Q2 | $51K | Sell |
5,171
-43,582
| -89% | -$301K | ﹤0.01% | 5948 |
|
|
2018
Q1 | $259K | Buy |
+48,753
| New | +$348K | ﹤0.01% | 4617 |
|
|
2017
Q4 | – | Sell |
-393
| Closed | -$6K | – | 8249 |
|
|
2017
Q3 | $6K | Sell |
393
-65,241
| -99% | -$986K | ﹤0.01% | 7179 |
|
|
2017
Q2 | $1.23M | Buy |
65,634
+64,169
| +4,380% | +$1.45M | ﹤0.01% | 3439 |
|
|
2017
Q1 | $31K | Sell |
1,465
-926
| -39% | -$17.7K | ﹤0.01% | 5846 |
|
|
2016
Q4 | $36K | Buy |
+2,391
| New | +$32.5K | ﹤0.01% | 6100 |
|
Other funds holding RARX
UBS Group's RARX Position: Q2 2020 in Review
UBS Group sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 47,824 shares — an estimated $2.3M sold.
UBS Group first reported a position in RARX in Q4 2016 and held it in 12 quarters. The position peaked at $2.65M in Q3 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.
- UBS Group reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
- UBS Group sold 47,824 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $2.3M.
- UBS Group first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 12 quarters.
- UBS Group's Ra Pharmaceuticals, Inc. Common Stock position peaked at $2.65M in Q3 2019.
- 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.
Based on UBS Group's 13F filing for Q2 2020, filed 31 Jul 2020.